GlassScriptPhysician profile
Kimberly Cook
NPI 1164851598
$3,602.67
in general payments reported to CMS, 2019-2025
35 companies · $810 in 2025
The $810 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $871 · 2023: $643 · 2024: $1,107 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $664.53 | 2022-2025 | Tavneos, Enbrel, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.12 | 2021-2025 | Ofev, Spiriva Respimat, Cyltezo |
| Mallinckrodt Hospital Products INC. | $339.39 | 2022-2025 | Acthar |
| Abbott Laboratories | $280.53 | 2021-2024 | Freestyle Libre 3 |
| Ucb, INC. | $214.53 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $166.67 | 2023-2024 | Saphnelo, Andexxa |
| Corcept Therapeutics | $160.95 | 2022-2024 | Korlym |
| Dexcom, INC. | $145.29 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $120.57 | 2024 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $111.24 | 2025 | Zerbaxa |
| Baxter Healthcare | $93.95 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Pfizer INC. | $73.81 | 2022-2025 | |
| United Therapeutics Corporation | $57.25 | 2024-2025 | Tyvaso, Tyvaso |
| Kyowa Kirin, INC. | $54.71 | 2024 | Crysvita |
| Melinta Therapeutics, LLC | $54.63 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $52.06 | 2021-2022 | |
| Janssen Biotech, INC. | $49.76 | 2023-2024 | Tremfya |
| Alexion Pharmaceuticals, INC. | $47.68 | 2021-2022 | |
| Novo Nordisk INC | $46.28 | 2022-2024 | Rybelsus |
| Merz Pharmaceuticals, LLC | $41.29 | 2025 | Xeomin, Inbrija, Ampyra |
| Galderma Laboratories, L.P. | $39.32 | 2025 | Nemluvio |
| Glaxosmithkline, LLC. | $37.71 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.58 | 2022-2023 | Glassia |
| Boston Scientific Corporation | $27.64 | 2024 | Spaceoar Vue System - 10ml |
| Stryker Corporation | $25.00 | 2024 | Universal Neuro 3, Duramatrix, Adherus Autospray Et Dural Sealant |
| Beta Bionics, INC. | $24.15 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sobi, INC | $22.29 | 2025 | |
| Travere Therapeutics, INC. | $20.98 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $17.65 | 2022 | |
| Daiichi Sankyo INC. | $17.15 | 2022 | |
| Genzyme Corporation | $14.37 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.17 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.15 | 2023 | Opsumit, Uptravi |
| Grifols USA, LLC | $14.11 | 2022 | |
| Biogen, INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.